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Abstract
Background: Cystic fibrosis (CF) is a common life-shortening genetic disease in which women have been
described to have worse outcomes than males, particularly in response to respiratory infections with Pseudo-
monas aeruginosa. However, as advancements in therapies have improved life expectancy, this gender disparity
has been challenged. The objective of this study is to examine whether a gender-based survival difference still
exists in this population and determine the impact of common CF respiratory infections on outcomes in males
versus females with CF.
Methods: We conducted a retrospective cohort analysis of 32,766 patients from the United States Cystic
Fibrosis Foundation Patient Registry over a 13-year period. Kaplan-Meier and Cox proportional hazards models
were used to compare overall mortality and pathogen based survival rates in males and females.
Results: Females demonstrated a decreased median life expectancy (36.0 years; 95% confidence interval [CI]
35.0–37.3) compared with men (38.7 years; 95% CI 37.8–39.6; p < 0.001). Female gender proved to be a
significant risk factor for death (hazard ratio 2.22, 95% CI 1.79–2.77), despite accounting for variables known
to influence CF mortality. Women were also found to become colonized earlier with several bacteria and to
have worse outcomes with common CF pathogens.
Conclusions: CF women continue to have a shortened life expectancy relative to men despite accounting for
key CF-related comorbidities. Women also become colonized with certain common CF pathogens earlier than
men and show a decreased life expectancy in the setting of respiratory infections. Explanations for this gender
disparity are only beginning to be unraveled and further investigation into mechanisms is needed to help
develop therapies that may narrow this gender gap.
Introduction
Cystic fibrosis (CF) is one of the most common genetic,fatal diseases in the United States. It is a multisystem
disorder that is characterized by nutritional deficiency and
recurrent respiratory infections due to thick mucus, caused by
lack of chloride transport across surface epithelium. Ad-
vancements in therapies have improved the median life ex-
pectancy from less than 5 years of age in the 1950s to nearly
40 years of age currently.1 These advancements began with
the advent of pancreatic enzyme supplementation in the
1940s to help with malnutrition and progressed to therapies
aimed at thinning airway mucus and fighting lung infections
such as dornase alpha and nebulized Tobramycin respec-
tively in the 1990s.2,3 Most recently ivacaftor, a therapy that
works to correct the underlying chloride channel protein
defect, was approved for patients with certain genetic mu-
tations.4 However, despite these improvements in treatment,
females with CF have worse outcomes than males for reasons
that are only beginning to be understood.5 Chronic respira-
tory infections remain the largest contributor to morbidity
and mortality in CF patients, and we therefore hypothesized
that females have more severe responses to respiratory in-
fections then males, contributing to their poorer outcomes.
A variety of respiratory diseases show a gender disparity in
prevalence and/or outcomes. For example, lymphangioleio-
myomatosis is a rare cystic lung disease of unknown etiology
well known to disproportionately affect young women of
childbearing age.6 In fact, very few men have ever been re-
ported to have this disease. This disease was hypothesized to
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be hormone mediated, but hormone based therapies have not
proven to be clearly beneficial as of yet.6 Observational data
suggest other diseases such as idiopathic pulmonary hyper-
tension are more prevalent in women, whereas idiopathic
pulmonary fibrosis, disproportionately affects men.7–9 Fur-
ther, in relationship to malignancies in the lung, malignant
mesothelioma disproportionately affects men, whereas wo-
men are more likely to have adenocarcinoma, yet men have
worse outcomes when affected by adenocarcinoma.10–12
Multiple epidemiologic studies have established that women
have worse outcomes than men in several airway diseases
beyond CF, such as asthma and chronic obstructive pulmo-
nary disease (COPD).5,13–16 Post-puberty, girls with asthma
have more frequent and severe exacerbations than boys.17 In
COPD, women develop evidence of airway obstruction after
fewer numbers of cigarettes per lifetime than men, and
women with severe COPD have a 50% increased risk of death
compared to men.16 In non-CF bronchiectasis, females have
been shown to have a higher prevalence of the disease than
males, particularly in conjunction with nontuberculous my-
cobacterial infections, despite no known difference in im-
munologic susceptibility.13
Reports that women with CF have lower survival rates than
men first appeared in the 1990s.18–20 Rosenfeld and col-
leagues published a large cohort analysis using data from the
United States Cystic Fibrosis Foundation Patient Registry
(CFFPR) between 1988 through 1992, showing that women
had shorter life expectancies than men.5 This difference was
significant even after adjusting for confounding morpho-
metric and nutritional factors. Another group demonstrated
that CF females acquired chronic Pseudomonas aeruginosa
infection, one of the most prevalent and virulent bacteria in
this population, at an earlier age (median of 9.5 years in
females and 11.2 years in males) and had amore rapid decline
in lung function after P. aeruginosa colonization.21 Since that
time, several reports have refuted the gender gap observation
in CF, arguing that improved airway clearance therapies have
narrowed the gender difference.22–25
Despite the controversy, multiple reports have evaluated
mechanisms behind the gender disparity in CF and focused
on the role of female sex hormones. In particular, estrogen
has been implicated as a hormone that decreases air surface
liquid on bronchial epithelial cells by modulating ion chan-
nels on airway epithelium and therefore renders CF females
at a greater disadvantage than males by enhancing mucus
viscosity. In addition, estrogen has been shown to promote
conversion of P. aeruginosa from a nonmucoid to mucoid
form in CF, which is the more drug resistant and pathogenic
form.22–25 Increasing evidence is demonstrating that patho-
gens beyond P. aeruginosa are important variables in sur-
vival of patients with CF, including methicillin resistant
Staphylococcus aureus (MRSA).26
We, therefore, sought to utilize the United States CFFPR to
determine if a survival difference remains in men and women
with CF and evaluate the effect of respiratory infections on
outcomes between males and females with CF.
Methods
Participants
The CF Foundation Patient Registry contains demographic
and clinical data collected at United States centers accredited
by the CF Foundation and captures 92% to 97% of CF deaths
reported in the U.S.20 The United States CFFPR has evolved
to allow the examination of more and more CF pathogens to
be feasible. Reported microbiology data in the CFFPR
changed in 1994 to include a much more detailed profile than
in the past. From 1994 to 1997, positive cultures were re-
ported annually.26 Cultures were reported quarterly from
1998 through 2002, and at each encounter since 2003. Due to
these changes in collection, we utilized only data from the
annual data set to stay consistent over the time course of
analysis. Positive culture data were defined as greater than or
equal to two positive cultures across annual data sets for all
bacteria included other than Burkholderia cepacia, which
was defined as present if ever positive. Subjects for this study
were CF patients with data entered from CFF-accredited care
centers between January 1, 1995 and December 31, 2007.
Design and statistical analysis
Differences in demographic variables were determined
using chi-squared tests for categorical variables and t-tests for
continuous variables. We performed a survival analysis using
Kaplan-Meier methodology. Age at entry into the cohort was
defined as age of diagnosis. The primary outcome was the
time from age at entry into the cohort until age at death from
any cause, as reported in previous CF literature.26 The CFF
registry captures 90 percent of patient deaths. Therefore, at
the end of the study period, subjects were either categorized
as dead or assumed to be alive, and censored at their age on
December 31, 2007. Patients who underwent lung trans-
plantation were excluded. A log-rank analysis was used to
determine statistical differences in survival times between
men and women.
Cox proportional hazards models were used to analyze the
effects of multiple variables on mortality. Time independent
variables included were gender, race, CF genotype, date of
birth (cohorts were grouped by increments of 10 years), cause
of death, highest recorded sweat chloride value, pancreatic
functional status (defined as whether or not the subject was
using enzyme replacements), and presence or absence CF-
related diabetes (CFRD). Diabetes was defined as whether or
not the subject was listed as having CFRD or having a he-
moglobin A1c greater than 6.1.
27 Positive culture data were
defined as greater than or equal to two positive cultures across
annual data sets for all bacteria included other than B. cepacia,
which was defined as present if ever positive. Burkholderia
species information in the CFFPR does not differentiate mu-
coid from nonmucoid strains.
Time-dependent variables analyzed in the Cox propor-
tional hazard model were height and body mass index (BMI)
(z-scores), percent of forced expiratory volume in 1 second
(%FEV1), and rate of pulmonary exacerbations. Pulmonary
exacerbations were defined as use of intravenous antibiotics
for the purpose of treating a CF exacerbation. The effect of
continuous variables on mortality rates was further analyzed
using a lag-two method in order to account for possible dif-
ferences that may be due to imbalances in severity of illness
or aggressive treatment in the last years of life. In other
words, for time-dependent covariates, the covariate values at
age t-2 were used as predictors. Similar results were noted
using both methods of analysis and no interactions were
found between variables in the model. Individual pathogen
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influence on gender-based survival was analyzed using a
multivariate Cox proportional hazard analysis with gender as
a time independent variable and pathogen as a time-dependent
variable.
Age of pathogen acquisition as a mean with standard de-
viations and life expectancy after infection as a median with
confidence intervals were evaluated using independent two-
tailed t-tests. All data was analyzed using SAS software,
version 9.3 (SAS Institute). This study was approved by the
University of Texas Southwestern Medical Center Institu-
tional Review Board and was waived of informed consent




This study is a retrospective cohort analysis of 34,693
patients in the CFFPR (Fig. 1). Patients who received an
organ transplant (1,857) were excluded given that their sur-
vival would be altered by organ transplantation, leaving
32,836 subjects. A group of 70 subjects were found to have a
negative value for survival, likely due to data entry error and
were also excluded. Therefore, a total of 32,766 subjects were
included in the final analysis with 17,174 males and 15,592
females, of which 12.6% of males died and 14.3% of females
died (Fig. 1).
Comparisons of important CF demographic and clinical
characteristics between men and women in this cohort are
shown in Table 1. Distribution of race and genotypes in males
and females were similar though females had lower sweat
tests. Date of birth cohort and lung function as measured by
%FEV1 were statistically different between groups but
without extreme imbalances in subgroups. The percentage of
men with pancreatic insufficiency was higher, while the
highest risk for an abnormal BMI was in females. CF-related
diabetes was more prevalent in females. Presence of mucoid
and nonmucoid P. aeruginosa, MRSA, and Achromobacter
xylosoxidans was higher in females, while presence of
B. cepacia was higher in males. Finally, more females died
of respiratory and cardio-respiratory causes than males and
females had on average an increased number of acute exac-
erbations per year than males.
Survival analysis
Kaplan-Meier analysis demonstrated a significant differ-
ence in survival of CF males versus females ( p < 0.001) with
a median life expectancy of 38.7 years (95% confidence in-
terval [95% CI] 37.8–39.6) in males and 36.0 years (95% CI
35.0 37.3) in females (Fig. 2). Risk of death was analyzed
using Cox proportional analysis with all variables included in
this study (Table 2). Importantly, females were more likely to
die than males (hazard ratio [HR] 1.252, 95% CI 1.180–
1.328, p < 0.001). Variables that have been previously de-
scribed to impact survival in CF were similarly found to be
significant risk factors for death in our study, including BMI,
pancreatic insufficiency, %FEV1, CF-related diabetes, and
colonization with P. aeruginosa, MRSA, and B. cepa-
cia.18,19,28,29 Other pathogens found to be associated with
increased risk of death included Klebsiella pneumoniae, Es-
cherichia coli, A. xylosoxidans, other gram negative organ-
isms, and Aspergillus species, but not methicillin-sensitive
Staphylococcus aureus (MSSA) or Haemophilus infuenzae.
Mortality also increased with increasing number of pulmo-
nary exacerbations as described previously (1.7 in males and
2.2 in females, p < 0.001).30
In order to account for the influence of other variables on
gender-related outcomes, all variables from the univariate
analysis were included in a multivariate model (Table 3).
There remained an increased risk of death associated with
female gender (adjusted HR 2.227, 95% CI 1.790–2.771,
p < 0.0001). Other variables in the model associated with
increased risk of death when accounting for all other variables
included number of pulmonary exacerbations, pancreatic in-
sufficiency, CF-related diabetes, mucoid and nonmucoid
P. aeruginosa, MRSA, and B. cepacia, as previously re-
ported.18,19,29 Date of birth cohorts were included in the
multivariate model, but did not reveal statistical significance
and are therefore not displayed on Table 3.
Gender differences in age of infection and outcomes
We further evaluated gender-based differences in micro-
bial infection. We assessed mean age of first pathogen
FIG. 1. Diagram of the study population of cystic fibrosis
patients from the Cystic Fibrosis Foundation Patient Reg-
istry analyzed by gender. A total of 34,693 subjects were
evaluated for this analysis. Subjects who received a lung
transplant were excluded, resulting in 32,836 subjects. There
were 70 patients whose survival lengths (SURV) were found
to be less than zero and were therefore not included. There
remained 32,766 subjects, of whom 17,174 were men and
15,592 were women.
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Table 1. Demographic Characteristics of Male and Female Cystic Fibrosis Patients
Seen at Cystic Fibrosis Foundation-Accredited U.S. Care Centers
Male Female
n = 17,174 n= 15,592
(52.4%) (47.6%) p value
Racea 0.373
White 14,974 (87.2%) 13,653 (87.6%)
Hispanic 1,316 (7.6%) 1,145 (7.3%)
African American 734 (4.3%) 639 (4.1%)
Sweat chloride, mean – SD 99.1 – 20.8 98.3 – 21.0 < 0.001
n = 14,701 n= 13,192
CFTR genotype,a n (%) 0.116
F508del/F508del 6,853 (39.9%) 6,311 (40.5%)
F508del/Other 5,302 (30.9%) 5,043 (32.3%)
Other/Other 2,066 (12.0%) 1,821 (11.7%)
Date of birth cohort,a n (%) 0.0001
1958–1967 3,734 (21.7%) 3,687 (23.6%)
1968–1977 5,089 (29.6%) 4,643 (29.8%)
1978–1987 4,557 (26.5%) 4,040 (25.9%)
1988–1997 2,509 (14.6%) 2,098 (13.5%)
1998–2007 1,285 (7.5%) 1,116 (7.2%)
BMI risk,a,b n (%) < 0.001
Low ( ‡ 22) 2,265 (13.2%) 1,514 (9.7%)
Mild (20–21.9) 3,076 (17.9%) 2,919 (18.7%)
Moderate (18–19.9) 2,867 (16.7) 2,728 (17.5%)
High ( < 18) 8,966 (52.2%) 8,431 (54.1%)
Height (percent),b mean – SD 33.6 – 27.3% 34.9 – 27.3% < 0.001
n = 15,077 n= 13,711
FEV1,
a,b % predicted, n (%) < 0.001
> 80 5,645 (32.9%) 4,746 (30.4%)
60–79 2,690 (15.7%) 2,475 (15.9%)
40–59 2,114 (12.3%) 2,255 (14.5%)
< 40 6,725 (39.1%) 6,116 (39.2%)
Number of pulmonary exacerbations per year, mean – SD 1.7 – 3.1 2.2 – 3.4 < 0.001
n = 16,175 n= 14,667
Pancreatic insufficiency, n (%) 14,960 (87.1%) 13,093 (84.0) < 0.0001
CF-related diabetes, n (%) 2,214 (12.9%) 2,499 (16.0%) < 0.001
Pseudomonas aeruginosa, nonmucoid, n (%) 10,762 (62.7%) 10,222 (65.6%) < 0.0001
P. aeruginosa, mucoid, n (%) 8,442 (49.2%) 7,933 (50.9%) 0.002
MSSA, n (%) 14,521 (84.6%) 13,137 (84.3%) 0.456
MRSA, n (%) 4,277 (24.9%) 4,087 (26.2%) 0.007
Haemophilus influenzae, n (%) 9,902 (57.7%) 8,892 (57.0%) 0.251
Klebsiella pneumonia, n (%) 2,057(12.0%) 1,965 (12.6%) 0.085
Escherichia coli, n (%) 2,361 (13.8%) 2,329 (15.0%) 0.002
Achromobacter xylosoxidans, n (%) 5,070 (29.5%) 5,152 (33.0%) < 0.0001
Other gram negatives, n (%) 7,815 (45.5%) 7,198 (46.2%) 0.231
Burkholderia cepacia, n (%) 1,494 (8.7%) 1,221 (7.8%) 0.004
Aspergillus species, n (%) 5,783 (33.7%) 5,345 (34.3%) 0.246
Nontuberculous mycobacterium, n (%) 921 (5.4%) 893 (5.4%) 0.942
Cause of death,a n (%) < 0.001
Cardiopulmonary 1,823 (83.9%) 1,975 (88.2%)
Liver disease 63 (2.9%) 40 (1.8%)
Trauma 60 (2.8%) 18 (0.8%)
Suicide 12 (0.6%) 1 (0.1%)
Other 135 (6.2%) 127 (5.7%)
Unknown 79 (3.6%) 77 (3.4%)
aUsing a Bonferroni adjustment for multiple tests, a p value of < 0.002 should be considered statistically significant. This adjustment
controls the overall table error rate for the table at 0.05.
bVariables analyzed as lag 2 (2 years prior to death) for demographics.
BMI, body mass index; CFTR, cystic fibrosis transmembrane conductance regulator; F508del, deltaF508 gene mutation; FEV1, forced
expiratory volume in 1 second; MRSA, methicillin resistant staphylococcus aureus; MSSA, methicillin sensitive staphylococcus aureus;
SD, standard deviation
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acquisition and impact of infection on survival outcomes in
males versus females (Table 4). Females acquired non-
mucoid and mucoid P. aeruginosa, MSSA, MRSA, H. in-
fluenza, A. xylosoxidans, other gram negative organisms,
Aspergillus species, and nontuberculous mycobacterium at
significantly earlier ages than males, with the largest age
difference being in those with atypical mycobacterium.
Moreover, we evaluated gender specific mortality in males
versus females infected with these pathogens and found fe-
males to have a decreased life expectancy with all patho-
gens except K. pneumonia. Importantly, bacteria previously
reported to impact survival in CF such as P. aeruginosa,
MRSA, and B. cepacia were associated with poorer survival
outcomes in females.18,19,26 In addition, pathogens in a va-
riety of categories including nontuberculous mycobacterium,
fungi and bacteria showed disparities.
Finally, we examined the individual effects of pathogens on
female gender-based survival usingmultivariate analysis (Table
5). All pathogens increased female-based risk of death from the
original hazard ratio of 1.252. Interestingly, MRSA had a sim-
ilar impact on female risk of death as mucoid and nonmucoid P.
aeruginosa, implying that these gender-based mechanisms may
not be unique to gram negative bacteria or to P. aeruginosa.
Discussion
This large registry analysis demonstrated that women with
CF have worse outcomes than men, are predisposed to earlier
respiratory infections and have decrease life expectancies
once colonized with respiratory pathogens. We examined
32,766 CF patients in the United States, and show for the first
time that there are gender-based differences in microbial
infection in CF airways beyond P. aeruginosa.
Previous groups have demonstrated worse outcomes in CF
women relative to men, particularly in the 1990s.5,18,19 Since
that time, a host of literature has supported or refuted this
gender disparity. The potential explanations for a gender-
based difference in CF patients are only beginning to be re-
vealed. Some of the hypotheses for the worse outcomes in
women with CF have included descriptions of an immuno-
logic difference resulting in earlier infections and poorer
responses to organisms such as P. aeruginosa.21,31,32 Cho-
tirmall and colleagues demonstrated that estrogen induces
mucoid conversion of P. aeruginosa, a more antibiotic
resistant form of the bacteria, and showed an association
between increased exacerbations and mucoid conversion in
women with CF during high estrogen states.31 We found that
not only do women acquire P. aeruginosa at an earlier
age, but they also acquire MSSA, MRSA, H. influenzae,
A. xylosoxidans, B. cepacia, Aspergillus species, and non-
tuberculous mycobacterium at earlier ages, often even prior
to puberty. This earlier acquisition was combined with
FIG. 2. Kaplan Meier estimate of survival comparing
cystic fibrosis (CF) women with men seen at accredited U.S.
CF care centers from 1995 to 2007. Females had poorer
survival, with a median life expectancy of 36.0 years (95%
CI 35.0–37.3) versus 38.7 years (95% CI 37.8–39.6) in men
( p < 0.001).
Table 2. Univariate Cox Regression for Survival
Variables
Hazard ratio
(95% CI) p value
Female 1.252 (1.180–1.328) < 0.0001
Racea
White 0.771 (0.661–0.887) 0.0003
Hispanic 1.937 (1.720–2.181) < 0.0001
African American 1.191 (1.018–1.394) 0.0295
Sweat Chloride 1.001 (0.999–1.003) 0.2732
CFTR genotypea
F508del/F508del 1.068 (0.992–1.150) 0.0956
F508del/other 0.895 (0.828–0.967) 0.0049
Other/other 1.107 (0.982–1.248) 0.0824
Date of birth cohorta
1958–1967 0.512 (0.468–0.560) < 0.0001
1968–1977 1.014 (0.950–1.083) 0.6695
1978–1987 1.414 (1.321–1.512) < 0.0001
1988–1997 1.193 (1.072–1.328) 0.0013
1998–2007 1.668 (1.309–2.124) < 0.0001
BMI (z-score)b 0.245 (0.231–.0261) < 0.0001
Height (z-score)b 0.687 (0.676–0.697) < 0.0001




1.141 (1.137–1.146) < 0.001
Pancreatic insufficiency 1.403 (1.062–1.854) 0.0173
CF-related diabetes 2.509 (2.035–3.092) < 0.0001
Pseudomonas aeruginosa,
nonmucoid
1.360 (1.169–1.583) < 0.0001
P. aeruginosa, mucoid 2.183 (1.835–2.598) < 0.0001
MSSA 0.714 (0.627–0.813) < 0.0001
MRSA 2.371 (1.999–2.811) < 0.0001
Haemophilus influenzae 0.562 (0.446–0.708) < 0.0001
Klebsiella pneumonia 2.197 (1.498–3.221) 0.0003
Escherichia coli 2.150 (1.514–3.054) 0.0001
Alcaligenes xylosoxidans 2.765 (2.246–3.404) < 0.0001
Achromobacter
xylosoxidans
1.780 (1.473–2.152) < 0.0001
Other gram negatives 1.641 (1.372–1.963) < 0.0001
Burkholderia cepacia 2.615 (2.104–3.251) < 0.0001




aUsing a Bonferroni adjustment for multiple testing, a p value
of < 0.0016 should be considered statistically significant. This
adjustment controls the overall table error rate for the table at 0.05.
bBMI and height calculated as z-scores using infant National Center
for Health Statistics (NHS) and Centers for Disease Control and
Prevention (CDC) tables.22
95% CI, 95% confidence interval; CFTR, cystic fibrosis trans-
membrane conductance regulator.
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increased mortality in women versus men in those with
mucoid and nonmucoid P. aeruginosa, MRSA, A. xylosox-
idans, B. cepacia, Aspergillus species, and nontuberculous
mycobacterium among others. Therefore the sensitivity of
women to infections in CF is not unique to P. aeruginosa and
spans other gram negative organisms, gram positive organ-
isms, nontuberculous mycobacterium, and fungal infections.
Descriptions of a gender disparity in nontuberculous myco-
bacterial infections outside of CF have been well described
where women are at increased risk for infection, but primarily
later in life, particularly after menopause.33–35 A genetic
basis may underlie this as at least one study found that 36%
of patients with mycobacterial infection who did not have
CF did carry one cystic fibrosis transmembrane conductance
regulator (CFTR) disease-causing gene, while others have
hypothesized morphometric or nutritional explanations.33–35
Though the cause of the gender disparity in infectious sus-
ceptibility is unclear, preventing early acquisition of in-
fections serves as a potential avenue of future studies and
treatments.
Several groups have also reported that sex hormones al-
ter components of the mucociliary apparatus, comprised of
mucus, cilia, and the airway epithelial air surface liquid layer.
The mucociliary apparatus serves as a unique mechanism by
which the airways protect the lungs from infection by trap-
ping pathogens and propelling them out of the lungs. Reports
demonstrated that sex hormones impact airway epithelial
cell apical sodium and chloride transport,36,37 alter airway
surface liquid (ASL) volume,38 influence inflammatory me-
diators that can predispose to infection and colonization,31
and change cilia beat frequency in the airways.39 It is still
unknown if these effects directly translate to poorer female
outcomes; however, estrogen was shown to decrease chloride




ratio (95% CI) p value
Female 2.227 (1.790–2.771) < 0.0001
White race 0.457 (0.256–0.815) 0.008
Hispanic race 1.723 (1.284–2.313) 0.0003
African American race 0.443 (0.215–0.912) 0.027
F508del/F508del 0.749 (0.548–1.023) 0.069
F508del/other 0.913 (0.667–1.250) 0.571
BMIa (z-score) 0.348 (0.264–0.459) < 0.0001
Heighta (z-score) 0.609 (0.564–0.657) < 0.0001
FEV1, % predicted 0.955 (0.949–0.960) < 0.0001
Number of pulmonary
exacerbations per year
1.088 (1.069–1.107) < 0.0001
Pancreatic insufficiency 7.914 (2.871–21.814) < 0.0001




P. aeruginosa, mucoid 1.413 (1.175–1.775) 0.003
MSSA 0.896 (0.732–1.097) 0.288
MRSA 1.544 (1.222–1.952) 0.0003
Haemophilus influenzae 0.636 (0.412–0.981) 0.041
Klebsiella pneumoniae 2.104 (1.113–3.975) 0.022




Other gram negatives 1.264 (0.957–1.670) 0.099
Burkholderia cepacia 1.638 (1.120–2.397) 0.011




aBMI and height calculated as z-scores using infant NHS and
CDC tables.30 [30]















Pseudomonas aeruginosa, nonmucoid M 10,762 10.87– 9.44 < 0.0001 41.7 (40.5–43.6) < 0.0001
F 10,222 10.03– 9.12 39.5 (38.2–40.9)
P. aeruginosa, mucoid M 8,442 13.32– 8.99 < 0.0001 41.5 (39.6–43.5) < 0.0001
F 7,933 12.46– 8.80 38.9 (38.0–40.7)
MSSA M 14,521 5.68 – 7.65 0.0008 39.8 (38.8–41.7) < 0.0001
F 13,137 5.37 – 7.38 37.6 (36.1–38.6)
MRSA M 4,277 12.40– 9.33 0.0007 41.5 (38.8–45.9) 0.0003
F 4,087 11.72– 9.12 40.7 (38.6–44.6)
Haemophilus influenzae M 9,902 6.16 – 7.52 0.0208 39.9 (38.8–42.2) < 0.0001
F 8,892 5.91 – 7.44 39.0 (37.8–40.9)
Klebsiella pneumoniae M 2,057 4.42 – 8.36 0.2930 40.0 (36.0–45.1) 0.0215
F 1,965 4.70 – 8.50 40.3 (35.0–45.2)
Escherichia coli M 2,070 4.96 – 8.87 0.5230 41.1 (36.8–45.9) 0.0013
F 1,965 4.78 – 8.52 38.9 (33.7–43.6)
Achromobacter xylosoxidans M 5,070 10.47– 9.02 0.0104 40.3 (38.8–43.7) < 0.0001
F 5,152 10.01– 8.83 38.5 (36.5–40.1)
Gram negatives M 7,815 8.71 – 9.43 0.0130 39.8 (38.5–41.0) < 0.0001
F 7,198 8.33 – 9.20 38.5 (36.6–39.7)
Burkholderia cepacia M 1,494 13.71– 8.41 0.0930 32.3 (31.3–33.7) 0.0008
F 1,221 13.16– 8.36 29.1 (28.0–30.4)
Aspergillus species M 5,783 13.13– 8.69 0.0003 41.5 (39.4–43.0) < 0.0001
F 5,345 12.54– 8.48 37.2 (35.4–38.6)
Nontuberculous mycobacteria M 921 16.27– 9.56 0.0006 46.4 (44.2–49.7) 0.0039
F 839 14.73– 9.24 44.6 (39.0–49.1)
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secretion via calcium mediated chloride channels in women
with CF as measured by changes in nasal potential difference,
and resulted in decreased airway surface liquid volume in CF
airway epithelium.38 This altered mucociliary clearance ap-
paratus may explain in part the disadvantage females have to
an array of pathogens in CF. Respiratory infections typically
trigger CF exacerbations in these patients and our group also
demonstrated that post-puberty CF women have a distinct
increase in rate of pulmonary exacerbations relative tomen.40
However, sex hormones are likely not the only explanation
for this gender disparity given that some reports suggest the
gender difference in CF may start before pubertal hormone
surges and that we demonstrated earlier bacterial infection in
females in this study prior to puberty in several cases.5
Other evidence hypothesizes possible differences in innate
immune response. One report showed that estrogen inhibited
interleukin-8 production in CF bronchial epithelial cells
in vitro and hypothesized that this would hinder neutrophil
recruitment and inflammatory responses in women.41–43 Others
have shown that estrogen inhibits the respiratory burst in
neutrophils, potentially hindering their killing capacity. Others
believe that the gender disparity has very little to do with host
immunity and more to do with gender-based differences in
morphometrics, such as airway diameter or airway branch
angles, which has not yet been evaluated. This type of data was
not available in this study given the lack of radiology imaging
in association with this database, but would be interesting to
explore at a more local CF center level.
Given that our study was retrospective in design, there are
several other inherent limitations to this study. For example,
variables not available in the registry that could impact re-
sults include patient exercise habits and adherence to medi-
cations. We also did not incorporate medications prescribed
in the analysis. Though we lacked these data, previous studies
showed no differences in adherence to therapies between
males and females with CF.44 Further, we were unable to
determine if earlier radiographic changes were seen in fe-
males versus males, as is often described to occur even prior
to changes in lung function or if bronchiectasis severity
scores were worse in women relative to men. These types of
analysis would be interesting to perform at single centers that
can perform radiographic correlates. In addition, details re-
garding pulmonary exacerbations such as which patients re-
ceived antibiotics for a true exacerbation versus a ‘‘tune-up’’
or ‘‘clean-out’’ was also unavailable. The microbiology data
in this study suggests that women have a higher prevalence
and worse outcome once infected with several bacteria be-
yond P. aeruginosa, however, we submit that we excluded
transplant patients from this analysis, which could have im-
pacted the results. Finally, we did not have data on socio-
economic status or environmental factors that could impact
male versus female outcomes and acknowledge that these
kinds of variables could affect the results. Despite these
limitations, this is the largest analysis to suggest that women
with CF have worse outcomes in the setting of infections
beyond P. aeruginosa. Further work into mechanisms behind
this including the impact of hormones on innate immunity is
warranted.
Finally, the gender disparity in CF is not unique to this
airway disease. A host of literature supports worse outcomes
in females with asthma and COPD. Interestingly, this dis-
parity is opposite to that seen in the global United States
population where the life expectancy for females is 80.9
versus 76.3 in males as of 2010, a 4.6 year difference in favor
of women as opposed to the 2.7 year difference in favor of
men found in our analysis, demonstrating a theoretical 7.3
year disadvantage in women with CF relative to the general
population. Therefore, further research into the mechanisms
behind this disparity is warranted and may shed light into
potential therapeutic options such as hormone modulating
therapies that may be delivered directly to the airways.
Conclusions
In conclusion, in evaluating the impact of gender on out-
comes in a large CF cohort, females were found to have an
increased mortality, more commonly acquire infections at an
earlier age than males, and have shorter life expectancies
in the setting of respiratory infections. These findings were
seen in association with a number of pathogens including
gram positive, gram negative, fungal, and nontubercuous
mycobacterial organisms. This study corroborates a host of
literature describing potential disadvantages of women in
relation to airway diseases and supports the need for further
work to understand mechanisms behind this gender disparity.
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